{"id":9046,"date":"2023-03-15T16:50:11","date_gmt":"2023-03-15T15:50:11","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=9046"},"modified":"2024-04-30T14:04:17","modified_gmt":"2024-04-30T12:04:17","slug":"induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/","title":{"rendered":"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor"},"content":{"rendered":"
\n

Satoshi Tanida<\/a>\u00a01<\/a>\u00a02<\/a><\/sup>,\u00a0Keiji Ozeki<\/a>\u00a03<\/a><\/sup>,\u00a0Takahito Katano<\/a>\u00a03<\/a><\/sup>,\u00a0Mamoru Tanaka<\/a>\u00a03<\/a><\/sup>,\u00a0Takaya Shimura<\/a>\u00a03<\/a><\/sup>,\u00a0Eiji Kubota<\/a>\u00a03<\/a><\/sup>,\u00a0Hiromi Kataoka<\/a>\u00a03<\/a><\/sup>,\u00a0Takuya Takahama<\/a>\u00a02<\/a><\/sup>,\u00a0Shun Sasoh<\/a>\u00a02<\/a><\/sup>,\u00a0Yoshimasa Kubota<\/a>\u00a02<\/a><\/sup>,\u00a0Tesshin Ban<\/a>\u00a02<\/a><\/sup>,\u00a0Tomoaki Ando<\/a>\u00a02<\/a><\/sup>,\u00a0Makoto Nakamura<\/a>\u00a02<\/a><\/sup>,\u00a0Takashi Joh<\/a>\u00a02<\/a><\/sup>J Clin Med Res.\u00a02023 Mar;15(3):181-186.\u00a0doi: 10.14740\/jocmr4887<\/p>\n<\/div>\n\n

\n

Every-week (ew) adalimumab (ADA) maintenance following induction therapy with a standard induction regimen has recently been approved for use in Japan. The efficacy and safety of combination therapy with ew-ADA maintenance following standard induction regimen plus intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions\/week) for the treatment of refractory ulcerative colitis (UC) displaying failure of conventional, biologics and Janus kinase inhibitor have not been evaluated previously. The present retrospective study evaluated the 10-week efficacy of this combination therapy among refractory UC patients. Six patients were given initial ADA combination therapy (ADA at 160 mg in week 0, ADA 80 mg in week 2, and 40 mg in week 4, followed by ew-ADA at 40 mg\/week) plus intensive GMA. One patient (16.6%) achieved clinical remission and two patients (33.3%) achieved endoscopic improvement by week 10. After excluding two patients who discontinued treatment, mean full Mayo score (P = 0.14), endoscopic subscore (P = 0.18) and C-reactive protein level (P = 0.27) at 10 weeks were numerically decreased compared with baseline in the remaining four cases, although the differences were not significant. Use of ew-ADA maintenance following standard induction regimen plus intensive GMA appears unlikely to achieve satisfactory induction of clinical remission in UC patients for whom conventional agents, biologics and Janus kinase inhibitors have failed.<\/p>\n<\/div>\n\n

\n

Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor – PubMed (nih.gov)<\/a><\/p>\n<\/div>\n\n

\n

Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor – PMC (nih.gov)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Satoshi Tanida\u00a01\u00a02,\u00a0Keiji Ozeki\u00a03,\u00a0Takahito Katano\u00a03,\u00a0Mamoru Tanaka\u00a03,\u00a0Takaya Shimura\u00a03,\u00a0Eiji Kubota\u00a03,\u00a0Hiromi Kataoka\u00a03,\u00a0Takuya Takahama\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02J Clin Med Res.\u00a02023 Mar;15(3):181-186.\u00a0doi: 10.14740\/jocmr4887 Every-week (ew) adalimumab (ADA) maintenance following induction therapy with a standard induction regimen has recently been approved for use in Japan. The efficacy and safety of combination therapy with ew-ADA maintenance following standard induction regimen […]<\/p>\n","protected":false},"template":"","scientific_tags":[215,147,303,157,601,424,451,465,53,48,271,306],"class_list":["post-9046","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adalimumab","scientific_tags-clinical-remission","scientific_tags-combination","scientific_tags-efficacy","scientific_tags-endoscopic-response","scientific_tags-gma","scientific_tags-induction","scientific_tags-intensive","scientific_tags-refractory-patients","scientific_tags-retrospective","scientific_tags-study","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"\nInduction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Satoshi Tanida\u00a01\u00a02,\u00a0Keiji Ozeki\u00a03,\u00a0Takahito Katano\u00a03,\u00a0Mamoru Tanaka\u00a03,\u00a0Takaya Shimura\u00a03,\u00a0Eiji Kubota\u00a03,\u00a0Hiromi Kataoka\u00a03,\u00a0Takuya Takahama\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02J Clin Med Res.\u00a02023 Mar;15(3):181-186.\u00a0doi: 10.14740\/jocmr4887 Every-week (ew) adalimumab (ADA) maintenance following induction therapy with a standard induction regimen has recently been approved for use in Japan. The efficacy and safety of combination therapy with ew-ADA maintenance following standard induction regimen […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-30T12:04:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/\",\"name\":\"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-03-15T15:50:11+00:00\",\"dateModified\":\"2024-04-30T12:04:17+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/","og_locale":"es_ES","og_type":"article","og_title":"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte","og_description":"Satoshi Tanida\u00a01\u00a02,\u00a0Keiji Ozeki\u00a03,\u00a0Takahito Katano\u00a03,\u00a0Mamoru Tanaka\u00a03,\u00a0Takaya Shimura\u00a03,\u00a0Eiji Kubota\u00a03,\u00a0Hiromi Kataoka\u00a03,\u00a0Takuya Takahama\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02J Clin Med Res.\u00a02023 Mar;15(3):181-186.\u00a0doi: 10.14740\/jocmr4887 Every-week (ew) adalimumab (ADA) maintenance following induction therapy with a standard induction regimen has recently been approved for use in Japan. The efficacy and safety of combination therapy with ew-ADA maintenance following standard induction regimen […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/","og_site_name":"Adacyte","article_modified_time":"2024-04-30T12:04:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/","name":"Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-03-15T15:50:11+00:00","dateModified":"2024-04-30T12:04:17+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/induction-therapy-with-a-combination-of-weekly-adalimumab-plus-intensive-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-ulcerative-colitis-and-failure-of-conventional-agents-biologics\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/9046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=9046"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=9046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}